Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Impact of body mass index on surgical outcomes, narcotics consumption, and hospital costs following anterior cervical discectomy and fusion.
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
View in:
PubMed
subject areas
Anemia
Chronic Disease
Consumer Product Safety
Drug Labeling
Evidence-Based Medicine
Hematinics
Hemoglobins
Humans
Kidney Diseases
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Treatment Outcome
United States
United States Food and Drug Administration
Up-Regulation
authors with profiles
Ajaypal Singh